Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SVRA vs CAPR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SVRA Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–2 Matrix Metrics)

SVRA Overall Winner 6-Pillar Tally: SVRA 4 – 1 CAPR (1 Tie) Matrix Metrics: SVRA 6 – 2 CAPR

As of Nov 16, 2026, Savara Inc. (SVRA) is the stronger overall head-to-head candidate over Capricor Therapeutics Inc (CAPR) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). SVRA carries a Unified Composite Score of 57.7/100 (HOLD) at $4.42 (0.4x Forward P/E, 0.0% operating margin), whereas CAPR carries 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: SVRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.5); meanwhile CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SVRA vs CAPR
SVRA NASDAQ Head-to-Head Winner
Savara Inc.
Pharmaceutical Preparations
$4.42
-4.63% 1D
Market Cap $1.1B
TTM Revenue $1,000
Forward P/E 0.4x
Beta / 30D Vol 1.48β · 73% Vol
Unified Composite Score
57.7 / 100 HOLD
Tech 42.0 Fund 54.0 Flow 70.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.7%), weak momentum, RSI 43
RSI-14: 43.5 · SMA20: $4.73 · SMA50: $4.92
CAPR NASDAQ
Capricor Therapeutics Inc
Pharmaceutical Preparations
$8.47
-11.12% 1D
Market Cap $595.4M
TTM Revenue $11M
Forward P/E 78.7x
Beta / 30D Vol 1.52β · 152% Vol
Unified Composite Score
28.0 / 100 SELL
Tech 50.0 Fund 37.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.2% over 20 days), RSI 51
RSI-14: 51.3 · SMA20: $7.79 · SMA50: $8.08

6-Pillar Scorecard Institutional Category Breakdown (SVRA 4 – 1 CAPR)

Columns: Metric · SVRA · CAPR
1. Valuation Multiples SVRA
Forward P/E 0.4x 78.7x
Trailing P/E 0.4x 78.7x
PEG Ratio N/M 0.38x
EV / Revenue N/M 57.8x
2. Growth & Scale SVRA
Revenue Growth (YoY) +0.0% -7.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1,000 $11M
Market Cap $1.1B $595.4M
3. Profitability & Quality CAPR
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -151.0% -100.5%
4. Balance Sheet & Cash Flow SVRA
Cash Generation (TTM) -$131M -$146M
Cash Flow Margin N/A N/A
Net Cash / Leverage $551,000 Net Debt (0.28x D/E) $48M Net Debt (0.44x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SVRA
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 164.3% (17th %ile) 637.1% (89th %ile)
Put/Call OI Skew 0.05x (Call-Skewed) 1.57x (Put-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Markdown ACCUMULATION · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SVRA (6) vs CAPR (2)
Institutional Metric SVRA CAPR Criterion Row Edge
Market Capitalization
Scale
$1.1B $595.4M Larger Scale SVRA
Trailing P/E Ratio
Valuation
0.4x 78.7x Lower Multiple SVRA
Forward P/E Ratio
Valuation
0.4x 78.7x Lower Multiple SVRA
Revenue Growth (YoY)
Growth
+0.0% -7.9% Higher Growth SVRA
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-151.0% -100.5% Higher ROE CAPR
52-Week Range Position
Momentum
13% ($4–$7) 15% ($3–$40) Stronger Trend CAPR
Beta / 30D Volatility
Risk Regime
1.48β · 73% Vol 1.52β · 152% Vol Lower Realized Risk SVRA
Unified Institutional Score
Composite Signal
57.7 / 100 (HOLD) 28.0 / 100 (SELL) Higher Composite SVRA
Trailing 12M Revenue (USD)
Operating Scale
$1,000 $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 0.38x PEG · 57.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$131M ($551,000 Net Debt (0.28x D/E)) -$146M ($48M Net Debt (0.44x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CAPR +26.79 pp
SVRA: -0.56% · CAPR: +26.23%
3M Horizon CAPR +37.23 pp
SVRA: -17.6% · CAPR: +19.63%
6M Horizon SVRA +58.55 pp
SVRA: -12.03% · CAPR: -70.58%
1Y Horizon CAPR +42.92 pp
SVRA: +3.87% · CAPR: +46.79%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SVRA Revenue CAPR Revenue SVRA Op. Margin CAPR Op. Margin Margin Leader
FY2017 N/A $0M N/A -482.4% CAPR
FY2018 N/A $0M N/A -917.0% CAPR
FY2019 N/A $0M N/A -769.5% CAPR
FY2020 $0M $0M -19182.9% -4412.6% CAPR
FY2021 N/A $0M N/A -8549.9% CAPR
FY2022 N/A $0M N/A -1163.9% CAPR
FY2023 N/A $30M N/A -95.6% CAPR
FY2024 N/A $20M N/A -191.1% CAPR

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SVRA BREAKDOWN
92d in phase · OBV ACCUMULATION
Current IV 164.3%
IV Percentile 17th %ile
Put/Call OI Skew 0.05x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact SVRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CAPR CONSOLIDATION
56d in phase · OBV ACCUMULATION
Current IV 637.1%
IV Percentile 89th %ile
Put/Call OI Skew 1.57x (Put-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CAPR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SVRA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CAPR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $595.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SVRA vs CAPR Key Questions & Quantitative Answers

As of Nov 16, 2026, Savara Inc. (SVRA) is the stronger overall head-to-head candidate over Capricor Therapeutics Inc (CAPR) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). SVRA carries a Unified Composite Score of 57.7/100 (HOLD) at $4.42 (0.4x Forward P/E, 0.0% operating margin), whereas CAPR carries 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: SVRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.5); meanwhile CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SVRA leads the Growth & Scale pillar: SVRA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $1,000 TTM revenue (N/A gross margin, 0.0% operating margin), compared with CAPR at -7.9% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2017 to FY2024), SVRA cumulative revenue shifted N/A while CAPR shifted -33.3%. In operating R&D and SG&A reinvestment, SVRA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CAPR.

SVRA screens cheaper on headline valuation multiples. SVRA trades at 0.4x Forward P/E, 0.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CAPR trades at 78.7x Forward P/E, 78.7x Trailing P/E, 0.38x PEG, and 57.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SVRA (-151.0% ROE) versus CAPR (-100.5% ROE) capital efficiency.

In options market volatility and institutional positioning, SVRA carries 164.3% implied volatility (17th %ile, Compressed (<25th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.48β · 73% Vol realized risk). By comparison, CAPR carries 637.1% implied volatility (89th %ile, Extreme (>80th %ile)), a 1.57x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.52β · 152% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.